-+ 0.00%
-+ 0.00%
-+ 0.00%

Hanyu Pharmaceutical (300199.SZ): Pre-clinical studies of HY3003 tablets showed that the weight loss effect was superior to simeglutide

Zhitongcaijing·10/26/2026 17:57:01
Listen to the news

Zhitong Finance App News, Hanyu Pharmaceutical (300199.SZ) issued an announcement. The company recently completed a comparative study on pre-clinical pharmacodynamics of HY3003 tablets for weight loss. Research results showed that HY3003 tablets had a good weight loss effect on DIO mice and DIO rat obesity models. The weight loss effect was superior to that of the already marketed simeglutide tablets under the same experimental conditions, showing good development prospects for this variety.

According to the announcement, HY3003 tablets are a GLP-1R/GIPR/GCGR triple agonist oral formulation deployed by the company. It is intended for use in indications such as weight loss, type 2 diabetes, and metabolism-related fatty hepatitis. It is a major innovative drug type in the company's layout in the field of metabolic diseases.